English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The persistence of Hepatitis B surface antigen (HBsAg) in 156 patients with histopathologically proven acute viral hepatitis and 27 patients with chronic active hepatitis was assessed and correlated with their clinical and histopathological outcome; 1387 sequential serum samples were tested for HBsAg and its antibody (anti HBs). In the group with acute viral hepatitis, 86% of the patients who recovered, 67% of the patients who deteriorated histopathologically and 67% of the fatal cases carried HBsAg for up to 8 weeks only. While 56% of patients with chronic active hepatitis harboured HBsAg for 13-80 weeks, only 10% of the group with acute viral hepatitis did so. Of patients with chronic active hepatitis 37% deteriorated to cirrhosis and 11% died. Diverse anti-HBs-response patterns are reported and may have clinical significance.

Duration of hepatitis B surface antigenaemia and its correlation with the histopathological and clinical outcome in acute and chronic hepatitis